Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaNCT07008248
Real-World Clinical Study for Malignant Tumor-Induced Cachexia
An observational study of Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia and Multicenter Observational Study, run by Changchun GeneScience Pharmaceutical Co., Ltd. at 1 site in China.
Trial summary
This study is a non-interventional, multicenter observational study, aiming to assess the clinical characteristics and treatment outcomes of malignant tumor cachexia. The study is mainly divided into two cohorts: Retrospective Cohort: This cohort focuses on patients who have already been diagnosed with cachexia before… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
- How many people
- 0 participants
- Where
- 1 siteChina
- Study dates
- 15 Oct 2024to 31 Dec 2027
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cachexia patients with malignant tumors
Who may be able to join
- Aged 18 years or older (including 18 years).
- Malignant tumor confirmed by histology or cytology (both malignant solid tumors and malignant hematologic tumors are eligible for enrollment).
- Meeting the Fearon diagnostic criteria for cachexia.
- Life expectancy of ≥2 months (for the prospective cohort only).
- Able to sign the informed consent form (waiver of informed consent for the retrospective cohort).
Who cannot join
- Retrospective Cohort:
- Missing gender information.
- Missing date of birth or age information.
- Lack of any treatment or follow-up information after the date of meeting the diagnostic criteria for cachexia.
- Prospective Cohort: (Patients with any of the following are not eligible for enrollment in this study)
- Patients who are unable to receive any treatment for any reason.
- Patients who cannot undergo at least one follow-up.
- Patients whom the investigator deems unsuitable for participation in this study.
Trial locations and contacts
1 site in 1 country.
China1 site
Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University
Xuzhou, Jiangsu, 221000
About this study
This study is a non-interventional, multicenter observational study, aiming to assess the clinical characteristics and treatment outcomes of malignant tumor cachexia. The study is mainly divided into two cohorts:
Retrospective Cohort: This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study. It involves the retrospective collection and analysis of clinical data.
Prospective Cohort: This cohort includes patients who are diagnosed with cachexia after the start of this study. Data will be prospectively collected and analyzed during their subsequent diagnosis and treatment process.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective Cohort | This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study. It involves the retrospective collection and analysis of clinical data. | |
| Prospective Cohort | This cohort includes patients who are diagnosed with cachexia after the start of this study. Data will be prospectively collected and analyzed during their subsequent diagnosis and treatment process. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The value of weight increase compared to the baseline
Measured: through the observation period，an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start15 Oct 2024
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Why it stopped: Company strategy adjustment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaStudies of the same condition, open and under way.
- More trials run by Changchun GeneScience Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Xuzhou Central Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07008248
- Sponsor's protocol ID
- Megaxia RWS
- Status last verified
- Oct 2024
- First submitted
- 26 May 2025
- Last updated
- 8 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-World Clinical Study for Malignant Tumor-Induced Cachexia
- ClinicalTrials.gov ID
- NCT07008248
- Acronym / sponsor ID
- Megaxia RWS
- Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Company strategy adjustment
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Xuzhou Central Hospital
- Study start
- 15 Oct 2024 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a non-interventional, multicenter observational study, aiming to assess the clinical characteristics and treatment outcomes of malignant tumor cachexia. The study is mainly divided into two cohorts:
Retrospective Cohort: This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study. It involves the retrospective collection and analysis of clinical data.
Prospective Cohort: This cohort includes patients who are diagnosed with cachexia after the start of this study. Data will be prospectively collected and analyzed during their subsequent diagnosis and treatment process.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective Cohort | – | –This cohort focuses on patients who have already been diagnosed with cachexia before the initiation of this study. It involves the retrospective collection and analysis of clinical data. |
| Prospective Cohort | – | –This cohort includes patients who are diagnosed with cachexia after the start of this study. Data will be prospectively collected and analyzed during their subsequent diagnosis and treatment process. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cachexia patients with malignant tumors
Key inclusion criteria (5 listed)
- Aged 18 years or older (including 18 years).
- Malignant tumor confirmed by histology or cytology (both malignant solid tumors and malignant hematologic tumors are eligible for enrollment).
- Meeting the Fearon diagnostic criteria for cachexia.
- Life expectancy of ≥2 months (for the prospective cohort only).
- Able to sign the informed consent form (waiver of informed consent for the retrospective cohort).
Key exclusion criteria (8 listed)
- Missing gender information.
- Missing date of birth or age information.
- Lack of any treatment or follow-up information after the date of meeting the diagnostic criteria for cachexia.
- Prospective Cohort: (Patients with any of the following are not eligible for enrollment in this study)
- Patients who are unable to receive any treatment for any reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The value of weight increase compared to the baseline
Time frame: through the observation period，an average of 1 year
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2025.
Related trials for Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia
RecruitingPhase 4
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia and Multicenter Observational Study, run by Changchun GeneScience Pharmaceutical Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The value of weight increase compared to the baseline (time frame: through the observation period，an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.